Point72 Asset Management
APVO icon

Point72 Asset Management’s Aptevo Therapeutics APVO Stock Holding History

Point72 Asset Management’s Portfolio APVO Stock Details APVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,664
Closed -$435K – 3892
2025
Q3 		$435K Buy
+16,664
New +$669K ﹤0.01% 1966
2020
Q3 		– Hold
0
– -$1.32M – 912
2020
Q2 		– Hold
0
– – – 650
2020
Q1 		– Hold
0
– – – 650
2019
Q4 		– Hold
0
– – – 647
2019
Q3 		– Hold
0
– – – 637
2019
Q2 		– Hold
0
– – – 645
2019
Q1 		– Hold
0
– – – 701

Other funds holding APVO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Tradewinds Capital Management
Tradewinds Capital Management Bellingham, Washington $578M AUM 35.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Danske Bank
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Point72 Asset Management's APVO Position: Q4 2025 in Review

Point72 Asset Management sold out of Aptevo Therapeutics (APVO) in Q4 2025, closing a stake of 16,664 shares — an estimated $435K sold.

Point72 Asset Management first reported a position in APVO in Q3 2025 and held it in 1 quarter. The position peaked at $435K in Q3 2025. 11 funds tracked by Wall St. Rank hold APVO as of Q4 2025.

  • Point72 Asset Management reported no remaining Aptevo Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Point72 Asset Management sold 16,664 Aptevo Therapeutics shares in Q4 2025, an estimated $435K.
  • Point72 Asset Management first reported a position in Aptevo Therapeutics in Q3 2025 and held it in 1 quarter.
  • Point72 Asset Management's Aptevo Therapeutics position peaked at $435K in Q3 2025.
  • 11 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q4 2025.

Based on Point72 Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.